Brief Report: Mature Outcomes of 61.2 Gy Concomitant Boost Thoracic Radiotherapy in Limited Stage Small Cell Lung Cancer: CALGB 30610 (Alliance) / RTOG 0538 [0.03%]
Ⅲ期小细胞肺癌限局期患者胸部放疗采用61.2GY同期大剂量 boost 的长期疗效（联盟CALGB 30610/RT0G 0538）
Jeffrey A Bogart,Xiaofei Wang,Gregory Masters et al.
Jeffrey A Bogart et al.
Purpose: We report mature outcomes of limited stage small cell lung cancer (LSCLC) patients randomized to the 61.2 Gy concomitant boost (CB) thoracic radiotherapy (TRT) arm of CALGB 30610/RTOG 0538. The CB arm was discont...
Palbociclib Enhances Radiotherapy Efficacy by Promoting Apoptosis and Immune Modulation in Oral Squamous Cell Carcinoma [0.03%]
帕博西尼通过促进凋亡和免疫调节增强放射治疗对口腔鳞状细胞癌的疗效
Peng-Yi Lee,Pei-Hsuan Lee,Hsi-Feng Tu et al.
Peng-Yi Lee et al.
Background: Radiotherapy (RT) remains a cornerstone in the treatment of oral squamous cell carcinoma (OSCC), though its efficacy is often hindered by resistance mechanisms. Palbociclib, a selective CDK4/6 inhibitor, has s...
Outcomes of 5 versus 10 Fraction Radiation Therapy for Hepatocellular Carcinoma at a Veteran Affairs Hospital [0.03%]
退伍军人医院肝细胞癌5分割和10分割放疗疗效比较研究结果
Jamiluddin J Qazi,Abhishek Kumar,Devon Godfrey et al.
Jamiluddin J Qazi et al.
Purpose/objectives: To compare outcomes, liver toxicity, and survival between patients with hepatocellular carcinoma (HCC) treated with stereotactic body radiation therapy (SBRT) delivered in 5 versus 10 fractions within ...
GPNMB⁺ MDSCs Mediate Radiation-Induced Immune Suppression in Prostate Cancer and Are Targetable to Improve Systemic Control [0.03%]
GPNMB⁺MDSCs介导前列腺癌的放射诱导免疫抑制并可成为治疗靶点以改善全身控制能力
Oscar Mulvaney,Jin-Sung Chung,Masato Kobayashi et al.
Oscar Mulvaney et al.
Purpose: Stereotactic body radiation therapy (SBRT) provides excellent local control for localized prostate cancer (PC); however, systemic relapse remains the primary cause of mortality in high-risk patients, underscoring...
Use of hypofractionation among underserved populations undergoing radiotherapy for cancer: Implications for policy [0.03%]
放射治疗癌症的未服务人群中的低分割使用情况：对政策的影响
Nicole Z Murray,Joshua Sokeye,Joshua J Horns et al.
Nicole Z Murray et al.
Purpose: To examine the use of hypofractionation among underserved populations, with a focus on implications for policy. Materials and methods: ...
Peter J Koopmans,Rene Monshouwer,Jeroen Findhammer et al.
Peter J Koopmans et al.
Purpose: There is a strong desire to exploit daily MR-Linac (MRL) imaging for biomarker extraction and outcome prediction. Current prediction models are based on pretreatment and follow-up scans. If MRL data are to provid...
One Year After a Cyberattack: Lessons Learned and Dosimetric Analysis of Contingency Radiotherapy Plans [0.03%]
网络攻击一周年：经验教训及放射治疗计划的剂量学分析
Carla Cases,Artur Latorre-Musoll,Cristian Candela-Juan et al.
Carla Cases et al.
Purpose: Cyberattacks on health care institutions pose significant risks to patient care, particularly in radiotherapy departments, which are heavily reliant on digital systems. This study examines the impact of a ransomw...
Outcomes of Stage IVA Cervical Cancer Treated with Radiotherapy: A Systematic Review and Meta-Analysis [0.03%]
放射治疗IV期宫颈癌的疗效系统评价和 meta 分析
Surendra Kumar Saini,Shelly Srivastava,Anil Goel et al.
Surendra Kumar Saini et al.
Purpose: FIGO stage IVA cervical cancer, defined by bladder or rectal mucosal invasion without distant spread, is uncommon and understudied. This first meta-analysis exclusively on stage IVA cervical cancer aimed to synth...
Aly as a Key Regulator of DNA Repair and Immune Evasion in Esophageal Squamous Cell Carcinoma Radioresistance [0.03%]
ALY在食管鳞癌放疗抵抗中调控DNA修复及免疫逃逸的功能与机制研究
Shizhen Ding,Huichao Liang,Jianlin Wang et al.
Shizhen Ding et al.
Purpose: ESCC is frequently refractory to radiotherapy, in part due to efficient DNA damage repair and an immunosuppressive tumor microenvironment. We investigated whether ALYREF (Aly) coordinates radioresistance and immu...
Mechanisms, Microenvironments, and Models: Understanding Therapeutic Resistance in Glioblastoma [0.03%]
机制、微环境与模型：理解胶质母细胞瘤的治疗抵抗性
Amy J Wisdom,Heidi Temple,Yufei Cui et al.
Amy J Wisdom et al.
Glioblastoma (GBM) is the most common and lethal primary malignant brain tumor in adults. Despite aggressive multimodal therapy-including maximal safe resection, radiation therapy, and temozolomide chemotherapy-median survival remains appro...